Skip to main content

Loading market data...

CAI

Caris Life Sciences, Inc.

NASDAQ • United states

$32.35

+$1.24

(+3.99%)

Source: Yahoo Finance · Quote time Oct 21, 2026 13:55 UTC

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Caris Life Sciences, Inc. (CAI)

Unavailable

Quotes may be delayed

$9.14B

Market Cap

349,445

Volume

87.0

P/E Ratio

Unavailable

Div Yield

Caris Life Sciences, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 750 W JOHN CARPENTER FREEWAY, IRVING, TX
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

14 Sep 2026

Caris Life Sciences, Inc. reported Regulation FD disclosure

Caris Life Sciences, Inc. filed an 8-K covering Regulation FD disclosure.

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Caris Life Sciences, Inc..

7 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Caris Life Sciences, Inc..

5 Aug 2026

Caris Life Sciences, Inc. filed Form 10-Q

Caris Life Sciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

Caris Life Sciences, Inc. reported Operating or financial results

Caris Life Sciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$819.90M

Total assets (USD)$1.23B

Total liabilities (USD)$637.89M

Shareholders' equity (USD)$591.73M

Long-term debt (USD)$392.97M

Debt due within a year (USD)$178,000

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$263.71M	$26.93M	−$637,000	$0.00	10-Q · 5 Aug 2026
Q1 2026	$216.17M	$5.28M	−$510,000	$0.00	10-Q · 8 May 2026
Q4 2025	$292.89M	$88.41M	$81.96M	Unavailable	10-K · 3 Mar 2026
Q3 2025	$216.83M	$32.64M	$24.33M	$0.08	10-Q · 5 Nov 2025
Q2 2025	$181.40M	−$17.99M	−$71.79M	−$7.97	10-Q · 12 Aug 2025
Q1 2025	$120.92M	−$57.95M	−$102.58M	−$3.57	10-Q · 8 May 2026

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $31.00

-4.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

6

⏸️

Hold

2

📉

Sell

0

8 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 20:47 UTC Targets range 21.00–36.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

22

Sep 2026

Denton John Russel

See Remarks

Open-market sale

$31.82 per share

7,500 shares

17

Sep 2026

Brille Brian J

Director, See Remarks

Option exercise

$2.44 per share

400,000 shares

17

Sep 2026

Brille Brian J

Director, See Remarks

Open-market sale

$30.33 per share

400,000 shares

4

Sep 2026

Spetzler David Baxley

President

Option exercise

$2.44 per share

250,000 shares

4

Sep 2026

Spetzler David Baxley

President

Open-market sale

$24.76 per share

119,212 shares

3

Sep 2026

Spetzler David Baxley

President

Option exercise

$2.44 per share

1,000,000 shares

3

Sep 2026

Spetzler David Baxley

President

Open-market sale

$24.86 per share

478,000 shares

14

Aug 2026

CASTLEMAN PETER M

Director

Grant or award

Unavailable per share

13,192 shares

14

Aug 2026

PHILLIPS T DANNY

Director

Grant or award

Unavailable per share

13,192 shares

14

Aug 2026

Minor Lloyd

Director

Grant or award

Unavailable per share

13,192 shares

Top Shareholders

Fmr Llc

30,923,878 shares

0.449% change

6/30/2026

J. H. Whitney Equity Partners Vi, Llc

11,256,615 shares

-38.342% change

6/30/2026

Coatue Management Llc

9,819,992 shares

0% change

6/30/2026

Braidwell Lp

8,256,032 shares

3.079% change

6/30/2026

Sixth Street Partners Management Company, L.P.

7,327,041 shares

-49.066% change

6/30/2026

Pointstate Capital Lp

6,828,835 shares

-7.223% change

6/30/2026

Jpmorgan Chase & Co

6,558,514 shares

89.541% change

6/30/2026

Blackrock, Inc.

5,536,798 shares

13.994% change

6/30/2026

T. Rowe Price Investment Management, Inc.

5,079,141 shares

-9.11% change

6/30/2026

Vanguard Portfolio Management Llc

4,844,431 shares

28.894% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 20:47 UTC· 1 day ago

Research coverage and investment tools

Caris Life Sciences, Inc. (CAI) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Medical Specialities). Its last price was US$32.35 on 21 Oct 2026. That is 96% of the way from its 52-week low of US$14.19 to its 52-week high of US$33.13. Its market capitalisation was US$9.14 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$263.71M	$26.93M	−$637,000	$0.00	—	10.2%	—	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$216.17M	$5.28M	−$510,000	$0.00	—	2.4%	$22.53M	10-Q · 8 May 2026 (opens in a new tab)
Q4 2025	$292.89M	$88.41M	$81.96M	Unavailable	—	30.2%	$39.69M	10-K · 3 Mar 2026 (opens in a new tab)
Q3 2025	$216.83M	$32.64M	$24.33M	$0.08	—	15.1%	$55.33M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$181.40M	−$17.99M	−$71.79M	−$7.97	—	-9.9%	$5.90M	10-Q · 12 Aug 2025 (opens in a new tab)
Q1 2025	$120.92M	−$57.95M	−$102.58M	−$3.57	—	-47.9%	−$34.03M	10-Q · 8 May 2026 (opens in a new tab)

Cash and equivalents: $819.90M
Total assets: $1.23B
Total liabilities: $637.89M
Shareholders' equity: $591.73M
Long-term debt: $392.97M
Debt due within a year: $178,000

8-K · 14 Sep 2026

Caris Life Sciences, Inc. reported Regulation FD disclosure (opens in a new tab)

Caris Life Sciences, Inc. filed an 8-K covering Regulation FD disclosure.
SCHEDULE 13G/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Caris Life Sciences, Inc..
SCHEDULE 13G/A · 7 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Caris Life Sciences, Inc..
10-Q · 5 Aug 2026

Caris Life Sciences, Inc. filed Form 10-Q (opens in a new tab)

Caris Life Sciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

Caris Life Sciences, Inc. reported Operating or financial results (opens in a new tab)

Caris Life Sciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Denton John Russel See Remarks	22 Sep 2026	Open-market sale (S)	−7,500	$31.82	Form 4 (opens in a new tab)
Brille Brian J Director, See Remarks	17 Sep 2026	Option exercise (M)	+400,000	$2.44	Form 4 (opens in a new tab)
Brille Brian J Director, See Remarks	17 Sep 2026	Open-market sale (S)	−400,000	$30.33	Form 4 (opens in a new tab)
Spetzler David Baxley President	4 Sep 2026	Option exercise (M)	+250,000	$2.44	Form 4 (opens in a new tab)
Spetzler David Baxley President	4 Sep 2026	Open-market sale (S)	−119,212	$24.76	Form 4 (opens in a new tab)
Spetzler David Baxley President	3 Sep 2026	Option exercise (M)	+1,000,000	$2.44	Form 4 (opens in a new tab)
Spetzler David Baxley President	3 Sep 2026	Open-market sale (S)	−478,000	$24.86	Form 4 (opens in a new tab)
CASTLEMAN PETER M Director	14 Aug 2026	Grant or award (A)	+13,192	—	Form 4 (opens in a new tab)
PHILLIPS T DANNY Director	14 Aug 2026	Grant or award (A)	+13,192	—	Form 4 (opens in a new tab)
Minor Lloyd Director	14 Aug 2026	Grant or award (A)	+13,192	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Fmr Llc	6/30/2026	30,923,878	0.449%
J. H. Whitney Equity Partners Vi, Llc	6/30/2026	11,256,615	-38.342%
Coatue Management Llc	6/30/2026	9,819,992	0%
Braidwell Lp	6/30/2026	8,256,032	3.079%
Sixth Street Partners Management Company, L.P.	6/30/2026	7,327,041	-49.066%
Pointstate Capital Lp	6/30/2026	6,828,835	-7.223%
Jpmorgan Chase & Co	6/30/2026	6,558,514	89.541%
Blackrock, Inc.	6/30/2026	5,536,798	13.994%
T. Rowe Price Investment Management, Inc.	6/30/2026	5,079,141	-9.11%
Vanguard Portfolio Management Llc	6/30/2026	4,844,431	28.894%

Previous close: 31.11 USD
Day range: 30.93 – 32.75 USD
52-week range: 14.19 – 33.13 USD
Volume: 349,445
Market cap: $9.14B
Average volume: 4,766,607
P/E ratio: 87.0
EPS (FY 2025, diluted): −3.22 USD
Shares outstanding: 282.60M

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 13:55 UTC· 17 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:14 UTC· 59 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Market cap is the price × shares outstanding.

This research is not available for CAI yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.